Analysts have been eager to weigh in on the Healthcare sector with new ratings on Arrowhead Pharmaceuticals (ARWR) and Insulet (PODD).
Arrowhead Pharmaceuticals (ARWR)
B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on Arrowhead Pharmaceuticals today and set a price target of $57.00. The company’s shares closed last Friday at $40.43.
According to TipRanks.com, Mamtani is a 5-star analyst with an average return of 14.1% and a 49.3% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Madrigal Pharmaceuticals, and Galmed Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arrowhead Pharmaceuticals with a $65.71 average price target, which is a 50.8% upside from current levels. In a report issued on July 29, Chardan Capital also reiterated a Buy rating on the stock with a $81.00 price target.
See today’s analyst top recommended stocks >>
Insulet (PODD)
BTIG analyst Marie Thibault maintained a Hold rating on Insulet today. The company’s shares closed last Friday at $225.71, close to its 52-week high of $228.79.
According to TipRanks.com, Thibault is a 4-star analyst with an average return of 26.2% and a 61.8% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Varian Medical Systems, and Edwards Lifesciences.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Insulet with a $229.13 average price target, which is a 6.4% upside from current levels. In a report released yesterday, Canaccord Genuity also maintained a Hold rating on the stock with a $210.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
